[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$ffgGp_6DUdVrQfa9Xfo35aqaU-VvZKXLVvvbY5ksj-90":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":12,"truncated":13,"activeTrials":14,"phase3Count":15,"totalEnrollment":16,"activePrograms":17,"nonDrugCount":18,"topConditions":19,"upcomingReadouts":39,"phaseBuckets":65,"rows":72},"Institut Pasteur",[4,6,7,8,9,10,11],"Institut Pasteur de Lille","Institut Pasteur du Cambodge","Institut Pasteur de Madagascar","Institut Pasteur, Cambodia","Institut Pasteur de Dakar","Institut Pasteur de Tunis",126,false,39,5,952568,7,100,[20,23,25,28,30,32,34,37],{"name":21,"count":22},"COVID-19",6,{"name":24,"count":15},"Dengue",{"name":26,"count":27},"Chikungunya",4,{"name":29,"count":27},"Healthy Volunteers",{"name":31,"count":27},"Leptospirosis",{"name":33,"count":27},"Arbovirus Infections",{"name":35,"count":36},"Zika",3,{"name":38,"count":36},"Covid19",[40,45,50,55,60],{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT05501470","Probiotic For the Improvement of Environmental Enteropathy in Pregnant Women in Senegal","2024-07-31","Probiotic",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT05897879","Impact of Bacterial Expression and Immune Response in the Severity of Pertussis","2025-11-16","Nasopharyngeal swab",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT05858502","Understanding the Determinants of Mucosal Immunity and Optimizing the Diagnosis of Infection With SARS-CoV-2 Variants","2026-03-15","Blood sample collection",{"nctId":56,"briefTitle":57,"date":58,"intervention":59},"NCT06718127","Description of the Immune Response to Yellow Fever Vaccination","2026-04-30","blood samples collection",{"nctId":61,"briefTitle":62,"date":63,"intervention":64},"NCT05821478","Efficacy of an Adapted Antibiotherapy in Hurley Stage 2 Hidradenitis Suppurativa Patients","2027-02-28","ROCEPHIN, metronidazole, RIFADIN, IZILOX, placebo combination therapy",[66,67,68,69,70,71],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[73,99,117,139,162,185,203,224,252,270,298,316,341,368,386,412,430,456,487,505,523,541,559,577,602,620,638,664,682,708,734,762,780,818,843,869,887,912,937,961,988,1006],{"intervention":64,"totalTrials":74,"cells":75},1,{"EARLY_PHASE1":76,"PHASE1":79,"PHASE2":81,"PHASE3":83,"PHASE4":95,"NA":97},{"trials":77,"activeCount":78},[],0,{"trials":80,"activeCount":78},[],{"trials":82,"activeCount":78},[],{"trials":84,"activeCount":74,"soonestReadout":63},[85],{"nctId":61,"briefTitle":62,"status":86,"phases":87,"primaryCompletion":63,"completion":88,"start":89,"enrollment":90,"conditions":91,"interventions":93},"RECRUITING",[69],"2028-02-27","2025-05-22",92,[92],"Hidradenitis Suppurativa",[64,94],"Lymecyclin and corresponding placebos of the experimental arm",{"trials":96,"activeCount":78},[],{"trials":98,"activeCount":78},[],{"intervention":94,"totalTrials":74,"cells":100},{"EARLY_PHASE1":101,"PHASE1":103,"PHASE2":105,"PHASE3":107,"PHASE4":113,"NA":115},{"trials":102,"activeCount":78},[],{"trials":104,"activeCount":78},[],{"trials":106,"activeCount":78},[],{"trials":108,"activeCount":74,"soonestReadout":63},[109],{"nctId":61,"briefTitle":62,"status":86,"phases":110,"primaryCompletion":63,"completion":88,"start":89,"enrollment":90,"conditions":111,"interventions":112},[69],[92],[64,94],{"trials":114,"activeCount":78},[],{"trials":116,"activeCount":78},[],{"intervention":44,"totalTrials":74,"cells":118},{"EARLY_PHASE1":119,"PHASE1":121,"PHASE2":123,"PHASE3":133,"PHASE4":135,"NA":137},{"trials":120,"activeCount":78},[],{"trials":122,"activeCount":78},[],{"trials":124,"activeCount":74,"soonestReadout":43},[125],{"nctId":41,"briefTitle":42,"status":86,"phases":126,"primaryCompletion":43,"completion":127,"start":128,"enrollment":129,"conditions":130,"interventions":132},[68],"2025-12-31","2024-06-06",76,[131],"Environmental Enteric Dysfunction",[44],{"trials":134,"activeCount":78},[],{"trials":136,"activeCount":78},[],{"trials":138,"activeCount":78},[],{"intervention":59,"totalTrials":74,"cells":140},{"EARLY_PHASE1":141,"PHASE1":143,"PHASE2":145,"PHASE3":147,"PHASE4":149,"NA":151},{"trials":142,"activeCount":78},[],{"trials":144,"activeCount":78},[],{"trials":146,"activeCount":78},[],{"trials":148,"activeCount":78},[],{"trials":150,"activeCount":78},[],{"trials":152,"activeCount":74,"soonestReadout":58},[153],{"nctId":56,"briefTitle":57,"status":86,"phases":154,"primaryCompletion":58,"completion":155,"start":156,"enrollment":157,"conditions":158,"interventions":161},[71],"2027-04-30","2024-09-30",38,[159,160],"Immunization","Infections",[59],{"intervention":49,"totalTrials":74,"cells":163},{"EARLY_PHASE1":164,"PHASE1":166,"PHASE2":168,"PHASE3":170,"PHASE4":172,"NA":174},{"trials":165,"activeCount":78},[],{"trials":167,"activeCount":78},[],{"trials":169,"activeCount":78},[],{"trials":171,"activeCount":78},[],{"trials":173,"activeCount":78},[],{"trials":175,"activeCount":74,"soonestReadout":48},[176],{"nctId":46,"briefTitle":47,"status":86,"phases":177,"primaryCompletion":48,"completion":178,"start":179,"enrollment":180,"conditions":181,"interventions":183},[71],"2026-11-16","2023-11-16",210,[182],"Bordetella Pertussis, Whooping Cough",[49,184],"Blood samples",{"intervention":184,"totalTrials":74,"cells":186},{"EARLY_PHASE1":187,"PHASE1":189,"PHASE2":191,"PHASE3":193,"PHASE4":195,"NA":197},{"trials":188,"activeCount":78},[],{"trials":190,"activeCount":78},[],{"trials":192,"activeCount":78},[],{"trials":194,"activeCount":78},[],{"trials":196,"activeCount":78},[],{"trials":198,"activeCount":74,"soonestReadout":48},[199],{"nctId":46,"briefTitle":47,"status":86,"phases":200,"primaryCompletion":48,"completion":178,"start":179,"enrollment":180,"conditions":201,"interventions":202},[71],[182],[49,184],{"intervention":54,"totalTrials":74,"cells":204},{"EARLY_PHASE1":205,"PHASE1":207,"PHASE2":209,"PHASE3":211,"PHASE4":213,"NA":215},{"trials":206,"activeCount":78},[],{"trials":208,"activeCount":78},[],{"trials":210,"activeCount":78},[],{"trials":212,"activeCount":78},[],{"trials":214,"activeCount":78},[],{"trials":216,"activeCount":74,"soonestReadout":53},[217],{"nctId":51,"briefTitle":52,"status":86,"phases":218,"primaryCompletion":53,"completion":219,"start":220,"enrollment":221,"conditions":222,"interventions":223},[71],"2026-06-18","2023-12-15",90,[21],[54],{"intervention":225,"totalTrials":74,"cells":226},"Chloroquine sulfate",{"EARLY_PHASE1":227,"PHASE1":229,"PHASE2":231,"PHASE3":233,"PHASE4":235,"NA":250},{"trials":228,"activeCount":78},[],{"trials":230,"activeCount":78},[],{"trials":232,"activeCount":78},[],{"trials":234,"activeCount":78},[],{"trials":236,"activeCount":78},[237],{"nctId":238,"briefTitle":239,"status":240,"phases":241,"primaryCompletion":242,"completion":243,"start":244,"enrollment":245,"conditions":246,"interventions":248},"NCT02118090","Assessment of Plasmodium Vivax Chloroquine Resistance in Cambodia:","COMPLETED",[70],"2014-12","2015-03","2014-05",73,[247],"Vivax Malaria",[225,249],"DHA-PP",{"trials":251,"activeCount":78},[],{"intervention":249,"totalTrials":74,"cells":253},{"EARLY_PHASE1":254,"PHASE1":256,"PHASE2":258,"PHASE3":260,"PHASE4":262,"NA":268},{"trials":255,"activeCount":78},[],{"trials":257,"activeCount":78},[],{"trials":259,"activeCount":78},[],{"trials":261,"activeCount":78},[],{"trials":263,"activeCount":78},[264],{"nctId":238,"briefTitle":239,"status":240,"phases":265,"primaryCompletion":242,"completion":243,"start":244,"enrollment":245,"conditions":266,"interventions":267},[70],[247],[225,249],{"trials":269,"activeCount":78},[],{"intervention":271,"totalTrials":74,"cells":272},"cotrimoxazole daily prophylaxis",{"EARLY_PHASE1":273,"PHASE1":275,"PHASE2":277,"PHASE3":279,"PHASE4":294,"NA":296},{"trials":274,"activeCount":78},[],{"trials":276,"activeCount":78},[],{"trials":278,"activeCount":78},[],{"trials":280,"activeCount":78},[281],{"nctId":282,"briefTitle":283,"status":240,"phases":284,"primaryCompletion":285,"completion":286,"start":287,"enrollment":288,"conditions":289,"interventions":292},"NCT01746199","Efficacy of Antifolates Against Malaria in HIV-infected Pregnant Women and the Emergence of Induced Resistance in Plasmodium Falciparum",[69],"2015-10","2019-12","2013-12",193,[290,291],"Malaria in Pregnancy","HIV Infection",[271,293],"sulphadoxine-pyrimethamine",{"trials":295,"activeCount":78},[],{"trials":297,"activeCount":78},[],{"intervention":293,"totalTrials":74,"cells":299},{"EARLY_PHASE1":300,"PHASE1":302,"PHASE2":304,"PHASE3":306,"PHASE4":312,"NA":314},{"trials":301,"activeCount":78},[],{"trials":303,"activeCount":78},[],{"trials":305,"activeCount":78},[],{"trials":307,"activeCount":78},[308],{"nctId":282,"briefTitle":283,"status":240,"phases":309,"primaryCompletion":285,"completion":286,"start":287,"enrollment":288,"conditions":310,"interventions":311},[69],[290,291],[271,293],{"trials":313,"activeCount":78},[],{"trials":315,"activeCount":78},[],{"intervention":317,"totalTrials":74,"cells":318},"Nafamostat Mesilate",{"EARLY_PHASE1":319,"PHASE1":321,"PHASE2":323,"PHASE3":325,"PHASE4":337,"NA":339},{"trials":320,"activeCount":78},[],{"trials":322,"activeCount":78},[],{"trials":324,"activeCount":78},[],{"trials":326,"activeCount":78},[327],{"nctId":328,"briefTitle":329,"status":330,"phases":331,"primaryCompletion":332,"completion":332,"start":333,"enrollment":334,"conditions":335,"interventions":336},"NCT04390594","Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in Senegal","TERMINATED",[69],"2023-02-08","2020-08-13",59,[21],[317],{"trials":338,"activeCount":78},[],{"trials":340,"activeCount":78},[],{"intervention":342,"totalTrials":74,"cells":343},"Azythromycin",{"EARLY_PHASE1":344,"PHASE1":346,"PHASE2":348,"PHASE3":350,"PHASE4":364,"NA":366},{"trials":345,"activeCount":78},[],{"trials":347,"activeCount":78},[],{"trials":349,"activeCount":78},[],{"trials":351,"activeCount":78},[352],{"nctId":353,"briefTitle":354,"status":240,"phases":355,"primaryCompletion":356,"completion":357,"start":358,"enrollment":359,"conditions":360,"interventions":362},"NCT03474276","Comparing Several Strategies to Manage Moderate Acute Malnutrition Among Children From 6 to 24 Months Old",[69],"2018-12-31","2019-06-30","2018-01-31",1357,[361],"Moderate Acute Malnutrition",[342,363],"Albendazole",{"trials":365,"activeCount":78},[],{"trials":367,"activeCount":78},[],{"intervention":363,"totalTrials":74,"cells":369},{"EARLY_PHASE1":370,"PHASE1":372,"PHASE2":374,"PHASE3":376,"PHASE4":382,"NA":384},{"trials":371,"activeCount":78},[],{"trials":373,"activeCount":78},[],{"trials":375,"activeCount":78},[],{"trials":377,"activeCount":78},[378],{"nctId":353,"briefTitle":354,"status":240,"phases":379,"primaryCompletion":356,"completion":357,"start":358,"enrollment":359,"conditions":380,"interventions":381},[69],[361],[342,363],{"trials":383,"activeCount":78},[],{"trials":385,"activeCount":78},[],{"intervention":387,"totalTrials":74,"cells":388},"CoronaVac\u002FCoronaVac",{"EARLY_PHASE1":389,"PHASE1":391,"PHASE2":393,"PHASE3":395,"PHASE4":408,"NA":410},{"trials":390,"activeCount":78},[],{"trials":392,"activeCount":78},[],{"trials":394,"activeCount":78},[],{"trials":396,"activeCount":78},[397],{"nctId":398,"briefTitle":399,"status":240,"phases":400,"primaryCompletion":401,"completion":402,"start":403,"enrollment":404,"conditions":405,"interventions":406},"NCT05668065","Immunogenicity of Heterologous Versus Homologous Prime Boost Schedule With mRNA and Inactivated COVID-19 Vaccines",[69],"2022-01-31","2022-06-25","2021-11-22",199,[21],[387,407],"CoronaVac\u002FBNT162b2",{"trials":409,"activeCount":78},[],{"trials":411,"activeCount":78},[],{"intervention":407,"totalTrials":74,"cells":413},{"EARLY_PHASE1":414,"PHASE1":416,"PHASE2":418,"PHASE3":420,"PHASE4":426,"NA":428},{"trials":415,"activeCount":78},[],{"trials":417,"activeCount":78},[],{"trials":419,"activeCount":78},[],{"trials":421,"activeCount":78},[422],{"nctId":398,"briefTitle":399,"status":240,"phases":423,"primaryCompletion":401,"completion":402,"start":403,"enrollment":404,"conditions":424,"interventions":425},[69],[21],[387,407],{"trials":427,"activeCount":78},[],{"trials":429,"activeCount":78},[],{"intervention":431,"totalTrials":74,"cells":432},"SC599",{"EARLY_PHASE1":433,"PHASE1":435,"PHASE2":437,"PHASE3":450,"PHASE4":452,"NA":454},{"trials":434,"activeCount":78},[],{"trials":436,"activeCount":78},[],{"trials":438,"activeCount":78},[439],{"nctId":440,"briefTitle":441,"status":240,"phases":442,"primaryCompletion":443,"completion":444,"start":445,"enrollment":446,"conditions":447,"interventions":449},"NCT00210288","Healthy Adult Volunteer Study for Two Doses of a Shigella Vaccine",[68],"2006-09","2007-04","2005-05",111,[448],"Shigella Infection",[431],{"trials":451,"activeCount":78},[],{"trials":453,"activeCount":78},[],{"trials":455,"activeCount":78},[],{"intervention":457,"totalTrials":74,"cells":458},"Injection SF2A-TT15 10 µg Adjuvanted",{"EARLY_PHASE1":459,"PHASE1":461,"PHASE2":463,"PHASE3":481,"PHASE4":483,"NA":485},{"trials":460,"activeCount":78},[],{"trials":462,"activeCount":78},[],{"trials":464,"activeCount":78},[465],{"nctId":466,"briefTitle":467,"status":240,"phases":468,"primaryCompletion":469,"completion":470,"start":471,"enrollment":472,"conditions":473,"interventions":475},"NCT04602975","A Study to Investigate the Safety and Immunogenicity of the SF2a-TT15 Synthetic Carbohydrate-based Conjugate Vaccine Against Shigella Flexneri 2a",[68],"2023-04-12","2023-11-15","2020-10-06",248,[474],"Healthy",[457,476,477,478,479,480],"Injection SF2A-TT15 10 µg","Injection Adjuvanted Placebo","Injection Placebo","Injection SF2A-TT15 2 µg Adjuvanted","Injection SF2A-TT15 2 µg",{"trials":482,"activeCount":78},[],{"trials":484,"activeCount":78},[],{"trials":486,"activeCount":78},[],{"intervention":476,"totalTrials":74,"cells":488},{"EARLY_PHASE1":489,"PHASE1":491,"PHASE2":493,"PHASE3":499,"PHASE4":501,"NA":503},{"trials":490,"activeCount":78},[],{"trials":492,"activeCount":78},[],{"trials":494,"activeCount":78},[495],{"nctId":466,"briefTitle":467,"status":240,"phases":496,"primaryCompletion":469,"completion":470,"start":471,"enrollment":472,"conditions":497,"interventions":498},[68],[474],[457,476,477,478,479,480],{"trials":500,"activeCount":78},[],{"trials":502,"activeCount":78},[],{"trials":504,"activeCount":78},[],{"intervention":477,"totalTrials":74,"cells":506},{"EARLY_PHASE1":507,"PHASE1":509,"PHASE2":511,"PHASE3":517,"PHASE4":519,"NA":521},{"trials":508,"activeCount":78},[],{"trials":510,"activeCount":78},[],{"trials":512,"activeCount":78},[513],{"nctId":466,"briefTitle":467,"status":240,"phases":514,"primaryCompletion":469,"completion":470,"start":471,"enrollment":472,"conditions":515,"interventions":516},[68],[474],[457,476,477,478,479,480],{"trials":518,"activeCount":78},[],{"trials":520,"activeCount":78},[],{"trials":522,"activeCount":78},[],{"intervention":478,"totalTrials":74,"cells":524},{"EARLY_PHASE1":525,"PHASE1":527,"PHASE2":529,"PHASE3":535,"PHASE4":537,"NA":539},{"trials":526,"activeCount":78},[],{"trials":528,"activeCount":78},[],{"trials":530,"activeCount":78},[531],{"nctId":466,"briefTitle":467,"status":240,"phases":532,"primaryCompletion":469,"completion":470,"start":471,"enrollment":472,"conditions":533,"interventions":534},[68],[474],[457,476,477,478,479,480],{"trials":536,"activeCount":78},[],{"trials":538,"activeCount":78},[],{"trials":540,"activeCount":78},[],{"intervention":479,"totalTrials":74,"cells":542},{"EARLY_PHASE1":543,"PHASE1":545,"PHASE2":547,"PHASE3":553,"PHASE4":555,"NA":557},{"trials":544,"activeCount":78},[],{"trials":546,"activeCount":78},[],{"trials":548,"activeCount":78},[549],{"nctId":466,"briefTitle":467,"status":240,"phases":550,"primaryCompletion":469,"completion":470,"start":471,"enrollment":472,"conditions":551,"interventions":552},[68],[474],[457,476,477,478,479,480],{"trials":554,"activeCount":78},[],{"trials":556,"activeCount":78},[],{"trials":558,"activeCount":78},[],{"intervention":480,"totalTrials":74,"cells":560},{"EARLY_PHASE1":561,"PHASE1":563,"PHASE2":565,"PHASE3":571,"PHASE4":573,"NA":575},{"trials":562,"activeCount":78},[],{"trials":564,"activeCount":78},[],{"trials":566,"activeCount":78},[567],{"nctId":466,"briefTitle":467,"status":240,"phases":568,"primaryCompletion":469,"completion":470,"start":471,"enrollment":472,"conditions":569,"interventions":570},[68],[474],[457,476,477,478,479,480],{"trials":572,"activeCount":78},[],{"trials":574,"activeCount":78},[],{"trials":576,"activeCount":78},[],{"intervention":578,"totalTrials":74,"cells":579},"Two COVID-19 vaccine candidate (TMV-083\u002FV-591) administrations - Low dose",{"EARLY_PHASE1":580,"PHASE1":582,"PHASE2":594,"PHASE3":596,"PHASE4":598,"NA":600},{"trials":581,"activeCount":78},[],{"trials":583,"activeCount":78},[584],{"nctId":585,"briefTitle":586,"status":240,"phases":587,"primaryCompletion":588,"completion":588,"start":589,"enrollment":221,"conditions":590,"interventions":591},"NCT04497298","Clinical Trial to Evaluate the Safety and Immunogenicity of the COVID-19 Vaccine",[67],"2021-05-12","2020-08-10",[21],[578,592,593],"Two COVID-19 vaccine candidate (TMV-083\u002FV-591) administrations - High dose","One COVID-19 vaccine candidate (TMV-083\u002FV-591) administration - High dose",{"trials":595,"activeCount":78},[],{"trials":597,"activeCount":78},[],{"trials":599,"activeCount":78},[],{"trials":601,"activeCount":78},[],{"intervention":592,"totalTrials":74,"cells":603},{"EARLY_PHASE1":604,"PHASE1":606,"PHASE2":612,"PHASE3":614,"PHASE4":616,"NA":618},{"trials":605,"activeCount":78},[],{"trials":607,"activeCount":78},[608],{"nctId":585,"briefTitle":586,"status":240,"phases":609,"primaryCompletion":588,"completion":588,"start":589,"enrollment":221,"conditions":610,"interventions":611},[67],[21],[578,592,593],{"trials":613,"activeCount":78},[],{"trials":615,"activeCount":78},[],{"trials":617,"activeCount":78},[],{"trials":619,"activeCount":78},[],{"intervention":593,"totalTrials":74,"cells":621},{"EARLY_PHASE1":622,"PHASE1":624,"PHASE2":630,"PHASE3":632,"PHASE4":634,"NA":636},{"trials":623,"activeCount":78},[],{"trials":625,"activeCount":78},[626],{"nctId":585,"briefTitle":586,"status":240,"phases":627,"primaryCompletion":588,"completion":588,"start":589,"enrollment":221,"conditions":628,"interventions":629},[67],[21],[578,592,593],{"trials":631,"activeCount":78},[],{"trials":633,"activeCount":78},[],{"trials":635,"activeCount":78},[],{"trials":637,"activeCount":78},[],{"intervention":639,"totalTrials":74,"cells":640},"Investigational HIV vaccine dose A",{"EARLY_PHASE1":641,"PHASE1":643,"PHASE2":656,"PHASE3":658,"PHASE4":660,"NA":662},{"trials":642,"activeCount":78},[],{"trials":644,"activeCount":78},[645],{"nctId":646,"briefTitle":647,"status":240,"phases":648,"primaryCompletion":649,"completion":649,"start":650,"enrollment":651,"conditions":652,"interventions":654},"NCT01320176","Study to Evaluate the Dosage and Safety of Two Intramuscular Injections of an Investigational Clade B HIV Vaccine",[67],"2011-11","2010-10",36,[653],"HIV",[639,655],"Investigational HIV vaccine dose B",{"trials":657,"activeCount":78},[],{"trials":659,"activeCount":78},[],{"trials":661,"activeCount":78},[],{"trials":663,"activeCount":78},[],{"intervention":655,"totalTrials":74,"cells":665},{"EARLY_PHASE1":666,"PHASE1":668,"PHASE2":674,"PHASE3":676,"PHASE4":678,"NA":680},{"trials":667,"activeCount":78},[],{"trials":669,"activeCount":78},[670],{"nctId":646,"briefTitle":647,"status":240,"phases":671,"primaryCompletion":649,"completion":649,"start":650,"enrollment":651,"conditions":672,"interventions":673},[67],[653],[639,655],{"trials":675,"activeCount":78},[],{"trials":677,"activeCount":78},[],{"trials":679,"activeCount":78},[],{"trials":681,"activeCount":78},[],{"intervention":683,"totalTrials":74,"cells":684},"Gentamicins-EDTA",{"EARLY_PHASE1":685,"PHASE1":687,"PHASE2":700,"PHASE3":702,"PHASE4":704,"NA":706},{"trials":686,"activeCount":78},[],{"trials":688,"activeCount":78},[689],{"nctId":690,"briefTitle":691,"status":240,"phases":692,"primaryCompletion":693,"completion":694,"start":695,"enrollment":696,"conditions":697,"interventions":699},"NCT04789928","Conservative Treatment of Catheter - Related Injections With Gentamicine\u002FEDTA",[67],"2023-12-31","2024-03-01","2021-01-05",8,[698],"Patients With Uncomplicated Long-term Central Venous Catheter-related Biofilm-related Infection",[683],{"trials":701,"activeCount":78},[],{"trials":703,"activeCount":78},[],{"trials":705,"activeCount":78},[],{"trials":707,"activeCount":78},[],{"intervention":709,"totalTrials":74,"cells":710},"MAG-TN3 + AS15",{"EARLY_PHASE1":711,"PHASE1":713,"PHASE2":726,"PHASE3":728,"PHASE4":730,"NA":732},{"trials":712,"activeCount":78},[],{"trials":714,"activeCount":78},[715],{"nctId":716,"briefTitle":717,"status":240,"phases":718,"primaryCompletion":719,"completion":720,"start":721,"enrollment":722,"conditions":723,"interventions":725},"NCT02364492","A Phase I Study of a Therapeutic Vaccine Candidate in Patients With Localized Breast Cancer at High-Risk of Relapse",[67],"2019-10","2021-11-11","2015-02",20,[724],"Breast Neoplasms",[709],{"trials":727,"activeCount":78},[],{"trials":729,"activeCount":78},[],{"trials":731,"activeCount":78},[],{"trials":733,"activeCount":78},[],{"intervention":735,"totalTrials":74,"cells":736},"SF2a-TT15 vaccine",{"EARLY_PHASE1":737,"PHASE1":739,"PHASE2":754,"PHASE3":756,"PHASE4":758,"NA":760},{"trials":738,"activeCount":78},[],{"trials":740,"activeCount":78},[741],{"nctId":742,"briefTitle":743,"status":240,"phases":744,"primaryCompletion":745,"completion":746,"start":747,"enrollment":748,"conditions":749,"interventions":752},"NCT02797236","SF2a-TT15 Conjugate Vaccine in Healthy Adult Volunteers",[67],"2017-06","2017-12","2016-09",64,[750,751],"Shigellosis","Bacillary Dysentery",[735,753],"SF2a-TT15 vaccine + adjuvant",{"trials":755,"activeCount":78},[],{"trials":757,"activeCount":78},[],{"trials":759,"activeCount":78},[],{"trials":761,"activeCount":78},[],{"intervention":753,"totalTrials":74,"cells":763},{"EARLY_PHASE1":764,"PHASE1":766,"PHASE2":772,"PHASE3":774,"PHASE4":776,"NA":778},{"trials":765,"activeCount":78},[],{"trials":767,"activeCount":78},[768],{"nctId":742,"briefTitle":743,"status":240,"phases":769,"primaryCompletion":745,"completion":746,"start":747,"enrollment":748,"conditions":770,"interventions":771},[67],[750,751],[735,753],{"trials":773,"activeCount":78},[],{"trials":775,"activeCount":78},[],{"trials":777,"activeCount":78},[],{"trials":779,"activeCount":78},[],{"intervention":781,"totalTrials":782,"cells":783},"biological samples",2,{"EARLY_PHASE1":784,"PHASE1":786,"PHASE2":788,"PHASE3":790,"PHASE4":792,"NA":794},{"trials":785,"activeCount":78},[],{"trials":787,"activeCount":78},[],{"trials":789,"activeCount":78},[],{"trials":791,"activeCount":78},[],{"trials":793,"activeCount":78},[],{"trials":795,"activeCount":78},[796,807],{"nctId":797,"briefTitle":798,"status":799,"phases":800,"primaryCompletion":801,"start":802,"enrollment":803,"conditions":804,"interventions":806},"NCT02074865","Children's Antibiotic Resistant Infections in Low Income Countries","UNKNOWN",[],"2014-03","2012-09",1000,[805],"Bacterial Infections",[781],{"nctId":808,"briefTitle":809,"status":240,"phases":810,"primaryCompletion":811,"completion":811,"start":812,"enrollment":813,"conditions":814,"interventions":817},"NCT03912246","Collection of Human Biological Samples for the Development and Validation of New Methods of Diagnosis and for the Realization of Expertises Diagnostics in the Field of Infectious Diseases and Tropical",[71],"2021-12-31","2009-04-27",800,[815,816],"Infectious Disease","Tropical Disease",[781],{"intervention":819,"totalTrials":74,"cells":820},"rabies vaccine",{"EARLY_PHASE1":821,"PHASE1":823,"PHASE2":825,"PHASE3":827,"PHASE4":829,"NA":831},{"trials":822,"activeCount":78},[],{"trials":824,"activeCount":78},[],{"trials":826,"activeCount":78},[],{"trials":828,"activeCount":78},[],{"trials":830,"activeCount":78},[],{"trials":832,"activeCount":78},[833],{"nctId":834,"briefTitle":835,"status":240,"phases":836,"primaryCompletion":837,"completion":837,"start":838,"enrollment":839,"conditions":840,"interventions":842},"NCT04829630","Immunity Persistence After Abridged Intradermal Rabies PEP",[71],"2023-02-01","2021-10-20",180,[841],"Rabies",[819],{"intervention":844,"totalTrials":74,"cells":845},"blood sampling",{"EARLY_PHASE1":846,"PHASE1":848,"PHASE2":850,"PHASE3":852,"PHASE4":854,"NA":856},{"trials":847,"activeCount":78},[],{"trials":849,"activeCount":78},[],{"trials":851,"activeCount":78},[],{"trials":853,"activeCount":78},[],{"trials":855,"activeCount":78},[],{"trials":857,"activeCount":78},[858],{"nctId":859,"briefTitle":860,"status":240,"phases":861,"primaryCompletion":862,"completion":862,"start":863,"enrollment":864,"conditions":865,"interventions":867},"NCT04012164","Viral and Microbial Circulation Between Humans, Domesticated and Wild Animals Along an Ecotone, Democratic Republic of Congo",[71],"2021-09-21","2019-03-15",60,[866],"Zoonotic Disease",[844,868],"stool collection",{"intervention":868,"totalTrials":74,"cells":870},{"EARLY_PHASE1":871,"PHASE1":873,"PHASE2":875,"PHASE3":877,"PHASE4":879,"NA":881},{"trials":872,"activeCount":78},[],{"trials":874,"activeCount":78},[],{"trials":876,"activeCount":78},[],{"trials":878,"activeCount":78},[],{"trials":880,"activeCount":78},[],{"trials":882,"activeCount":78},[883],{"nctId":859,"briefTitle":860,"status":240,"phases":884,"primaryCompletion":862,"completion":862,"start":863,"enrollment":864,"conditions":885,"interventions":886},[71],[866],[844,868],{"intervention":888,"totalTrials":74,"cells":889},"birth dose vaccination against hepatitis B strategy",{"EARLY_PHASE1":890,"PHASE1":892,"PHASE2":894,"PHASE3":896,"PHASE4":898,"NA":900},{"trials":891,"activeCount":78},[],{"trials":893,"activeCount":78},[],{"trials":895,"activeCount":78},[],{"trials":897,"activeCount":78},[],{"trials":899,"activeCount":78},[],{"trials":901,"activeCount":78},[902],{"nctId":903,"briefTitle":904,"status":240,"phases":905,"primaryCompletion":906,"completion":220,"start":907,"enrollment":908,"conditions":909,"interventions":911},"NCT04029454","Neovac 2 Burkina Faso: Impact of the Integration of Hepatitis B Birth Dose Vaccine Into the Infant Immunization Schedule",[71],"2023-08-31","2020-10-19",10000,[910],"Hepatitis B",[888],{"intervention":913,"totalTrials":74,"cells":914},"Genetic determinants analysis",{"EARLY_PHASE1":915,"PHASE1":917,"PHASE2":919,"PHASE3":921,"PHASE4":923,"NA":925},{"trials":916,"activeCount":78},[],{"trials":918,"activeCount":78},[],{"trials":920,"activeCount":78},[],{"trials":922,"activeCount":78},[],{"trials":924,"activeCount":78},[],{"trials":926,"activeCount":78},[927],{"nctId":928,"briefTitle":929,"status":799,"phases":930,"primaryCompletion":931,"completion":931,"start":932,"enrollment":933,"conditions":934,"interventions":936},"NCT03925272","Creation of a Prospective Cohort of Healthy and Sick Subjects and of a Collection of Associated Biological Resources, for the Study of the Immune System and of Its Genetic and Environmental Determinants.",[71],"2023-12-02","2011-02-02",2200,[935],"Immune System and Related Disorders",[913],{"intervention":938,"totalTrials":74,"cells":939},"50 ml blodd sampling",{"EARLY_PHASE1":940,"PHASE1":942,"PHASE2":944,"PHASE3":946,"PHASE4":948,"NA":950},{"trials":941,"activeCount":78},[],{"trials":943,"activeCount":78},[],{"trials":945,"activeCount":78},[],{"trials":947,"activeCount":78},[],{"trials":949,"activeCount":78},[],{"trials":951,"activeCount":78},[952],{"nctId":953,"briefTitle":954,"status":799,"phases":955,"primaryCompletion":956,"completion":956,"start":957,"enrollment":722,"conditions":958,"interventions":960},"NCT05290688","Cellular microRNA Signatures in Multiple Sclerosis",[71],"2024-09-15","2022-09-15",[959],"Multiple Sclerosis, Relapsing-Remitting",[938],{"intervention":962,"totalTrials":74,"cells":963},"Intramuscular (IM) rabies post-exposure prophylaxis",{"EARLY_PHASE1":964,"PHASE1":966,"PHASE2":968,"PHASE3":970,"PHASE4":972,"NA":974},{"trials":965,"activeCount":78},[],{"trials":967,"activeCount":78},[],{"trials":969,"activeCount":78},[],{"trials":971,"activeCount":78},[],{"trials":973,"activeCount":78},[],{"trials":975,"activeCount":78},[976],{"nctId":977,"briefTitle":978,"status":240,"phases":979,"primaryCompletion":980,"completion":981,"start":982,"enrollment":983,"conditions":984,"interventions":986},"NCT05684185","Immunogenicity Assessment of Subjects Receiving Rabies Post-exposure Prophylaxis in Cambodia",[],"2022-04-01","2022-04-30","2020-07-15",215,[985],"Rabies Post-exposure Prophylaxis",[962,987],"Intradermal (ID) rabies post-exposure prophylaxis",{"intervention":987,"totalTrials":74,"cells":989},{"EARLY_PHASE1":990,"PHASE1":992,"PHASE2":994,"PHASE3":996,"PHASE4":998,"NA":1000},{"trials":991,"activeCount":78},[],{"trials":993,"activeCount":78},[],{"trials":995,"activeCount":78},[],{"trials":997,"activeCount":78},[],{"trials":999,"activeCount":78},[],{"trials":1001,"activeCount":78},[1002],{"nctId":977,"briefTitle":978,"status":240,"phases":1003,"primaryCompletion":980,"completion":981,"start":982,"enrollment":983,"conditions":1004,"interventions":1005},[],[985],[962,987],{"intervention":1007,"totalTrials":74,"cells":1008},"Antivenom serum Inoserp Pan-Africa®",{"EARLY_PHASE1":1009,"PHASE1":1011,"PHASE2":1013,"PHASE3":1015,"PHASE4":1017,"NA":1019},{"trials":1010,"activeCount":78},[],{"trials":1012,"activeCount":78},[],{"trials":1014,"activeCount":78},[],{"trials":1016,"activeCount":78},[],{"trials":1018,"activeCount":78},[],{"trials":1020,"activeCount":78},[1021],{"nctId":1022,"briefTitle":1023,"status":240,"phases":1024,"primaryCompletion":1025,"completion":1025,"start":1026,"enrollment":1027,"conditions":1028,"interventions":1032},"NCT03326492","Evaluation of Anti-venoms Serum in Africa",[],"2021-09-14","2019-10-17",474,[1029,1030,1031],"Snake Bites","Antivenins","Snake Venoms",[1007]]